Loading news...
Shares of Billiontoone, Inc. (NASDAQ: BLLN - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the ten analysts that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and six have given a buy recommendation to the
BillionToOne, Inc. (BLLN) Q4 2025 Earnings Call Transcript
BillionToOne delivers strong growth in molecular diagnostics, achieving profitability and raising 2026 revenue guidance to $430–$445 million. BillionToOne's Q4 sales rose 113% to $96.1 million, driven by prenatal testing; oncology growth was slower sequentially but remains a long-term diversification lever. I view current guidance as conservative, with recent product launches and coverage deals not fully reflected in the outlook, supporting further upside potential.
Billiontoone, Inc. (NASDAQ: BLLN - Get Free Report) saw unusually-strong trading volume on Thursday following a stronger than expected earnings report. Approximately 713,533 shares changed hands during mid-day trading, an increase of 179% from the previous session's volume of 255,680 shares.The stock last traded at $72.51 and had previously closed at $80.83. The company reported $0.11
Although the revenue and EPS for BillionToOne (BLLN) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the fourth quarter and full year ended December 31, 2025 and raised guidance for full year 2026.
MENLO PARK, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for fourth quarter and full year ended December 31, 2025 after the market close on Wednesday, March 4, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day.
Advanced Biomed (NASDAQ: ADVB - Get Free Report) and Billiontoone (NASDAQ: BLLN - Get Free Report) are both services companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings. Profitability This table compares Advanced Biomed and Billiontoone's net
Singapore-based Napean Trading & Investment bought 233,333 shares of BillionToOne in the fourth quarter. The quarter-end position value increased by $19,095,973, reflecting the new acquisition of shares.
Billiontoone, Inc. (NASDAQ: BLLN - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the ten ratings firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and six have assigned a buy recommendation to the company. The
Northstar PGx™ and Northstar Select CH™ extend clinical insight and utility of Northstar Select® all from the same blood-draw MENLO PARK, Calif., Feb. 10, 2026 /PRNewswire/ -- BillionToOne , Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the launch of Northstar PGx and Northstar Select CH.
BillionToOne Expands Its Leadership in Hemolytic Disease of the Fetus and Newborn (HDFN) and Extends Fetal Antigen Testing to Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) MENLO PARK, Calif., Feb. 9, 2026 /PRNewswire/ -- BillionToOne , Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the launch of UNITY's expanded Red Blood Cell (RBC) Fetal Antigen NIPT and a first-and-only Platelet Fetal Antigen NIPT.
Billiontoone (NASDAQ: BLLN - Get Free Report) and Caris Life Sciences (NASDAQ: CAI - Get Free Report) are both mid-cap services companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation. Valuation and Earnings This table compares Billiontoone
Caris Life Sciences (NASDAQ: CAI - Get Free Report) and Billiontoone (NASDAQ: BLLN - Get Free Report) are both mid-cap services companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, institutional ownership and valuation. Analyst Recommendations This is a summary of
Caris Life Sciences (NASDAQ: CAI - Get Free Report) and Billiontoone (NASDAQ: BLLN - Get Free Report) are both mid-cap services companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership. Analyst Recommendations This is a breakdown of
Exploring Baillie Gifford (Trades, Portfolio)'s Fourth Quarter 2025 Investment Adjustments Baillie Gifford (Trades, Portfolio) recently submitted the 13F filin
Billiontoone, Inc. (NASDAQ: BLLN - Get Free Report) has been given a consensus rating of "Moderate Buy" by the nine brokerages that are presently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month target price
Integration enables seamless ordering and results delivery within Epic for UNITY Complete® and Northstar® tests, creating a better patient and provider experience MENLO PARK, Calif., Jan. 15, 2026 /PRNewswire/ -- BillionToOne , Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced a collaboration with Epic , the nation's most widely used comprehensive electronic health record (EHR).
MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reiterated the full year 2025 guidance of $293 million to $299 million with positive GAAP operating income and initiated the full year 2026 guidance.
Ultra-sensitive liquid biopsy is expanding precision medicine access for patients in Japan with treatment-resistant non-small cell lung cancer (NSCLC) MENLO PARK, Calif., Jan. 6, 2026 /PRNewswire/ -- BillionToOne , Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the selection of Northstar Select ® as the new liquid biopsy in LC-SCRUM-TRY- Japan, a nationwide, multi-center study to better elucidate the mechanisms of drug resistance and the characteristics of drug-resistant lung cancer.